TRADD Antibody (Rabbit mAb) [F18K8]

CatNo: F5886

    Application: Reactivity:
    • Lane 1: Jurkat, Lane 2: MCF7, Lane 3: K562
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    キーポイント

    WB
    転写条件(ウェット): 200 mA, 60 min

    使用情報

    Dilution
    1:500 - 1:1000
    1:100 - 1:200
    1:50 - 1:100
    1:30
    Application
    WB, IHC, IF, FCM
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    34 kDa 34 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール Human breast carcinoma tissue; Human liver tissue; Human fetal spleen tissue; Jurkat cells; MCF7 cells; HeLa cells; K562 cells
    ネガティブコントロール

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 60 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:500), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IF
    Experimental Protocol:
     
    Sample Preparation
    1. Adherent Cells: Place a clean, sterile coverslip in a culture dish. Once the cells grow to near confluence as a monolayer, remove the coverslip for further use.
    2. Suspension Cells: Seed the cells onto a clean, sterile slide coated with poly-L-lysine.
    3. Frozen Sections: Allow the slide to thaw at room temperature. Wash it with pure water or PBS for 2 times, 3 minutes each time.
    4. Paraffin Sections: Deparaffinization and rehydration. Wash the slide with pure water or PBS for 3 times, 3 minutes each time. Then perform antigen retrieval.
     
    Fixation
    1. Fix the cell coverslips/spots or tissue sections at room temperature using a fixative such as 4% paraformaldehyde (4% PFA) for 10-15 minutes.
    2. Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Permeabilization
    1.Add a detergent such as 0.1–0.3% Triton X-100 to the sample and incubate at room temperature for 10–20 minutes.
    (Note: This step is only required for intracellular antigens. For antigens expressed on the cell membrane, this step is unnecessary.)
    Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Blocking
    Add blocking solution and incubate at room temperature for at least 1 hour. (Common blocking solutions include: serum from the same source as the secondary antibody, BSA, or goat serum.)
    Note: Ensure the sample remains moist during and after the blocking step to prevent drying, which can lead to high background.
     
    Immunofluorescence Staining (Day 1)
    1. Remove the blocking solution and add the diluted primary antibody.
    2. Incubate the sample in a humidified chamber at 4°C overnight.
     
    Immunofluorescence Staining (Day 2)
    1. Remove the primary antibody and wash with PBST for 3 times, 5 minutes each time.
    2. Add the diluted fluorescent secondary antibody and incubate in the dark at 4°C for 1–2 hours.
    3. Remove the secondary antibody and wash with PBST for 3 times, 5 minutes each time.
    4. Add diluted DAPI and incubate at room temperature in the dark for 5–10 minutes.
    5. Wash with PBST for 3 times, 5 minutes each time.
     
    Mounting
    1. Mount the sample with an anti-fade mounting medium.
    2. Allow the slide to dry at room temperature overnight in the dark.
    3. Store the slide in a slide storage box at 4°C, protected from light.
     
    IHC
    Experimental Protocol:
     
    Deparaffinization/Rehydration
    1. Deparaffinize/hydrate sections:
    2. Incubate sections in three washes of xylene for 5 min each.
    3. Incubate sections in two washes of 100% ethanol for 10 min each.
    4. Incubate sections in two washes of 95% ethanol for 10 min each.
    5. Wash sections two times in dH2O for 5 min each.
    6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
     
    Staining
    1. Wash sections in dH2O three times for 5 min each.
    2. Incubate sections in 3% hydrogen peroxide for 10 min.
    3. Wash sections in dH2O two times for 5 min each.
    4. Wash sections in wash buffer for 5 min.
    5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
    6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
    7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
    8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
    9. Wash sections three times with wash buffer for 5 min each.
    10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
    11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
    12. Immerse slides in dH2O.
    13. If desired, counterstain sections with hematoxylin.
    14. Wash sections in dH2O two times for 5 min each.
    15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
    16. Mount sections with coverslips and mounting medium.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    TRADD Antibody (Rabbit mAb) [F18K8] detects endogenous levels of total TRADD protein.
    タンパク質の局在
    細胞質、細胞骨格、細胞核
    Uniprot ID
    Q15628
    Clone
    F18K8
    Synonym(s)
    Tumor necrosis factor receptor type 1-associated DEATH domain protein, TNFR1-associated DEATH domain protein, TNFRSF1A-associated via death domain, TRADD
    Background
    Tumor necrosis factor receptor type 1–associated death domain protein (TRADD) is a death-domain–containing adaptor encoded by the TRADD gene that binds directly to the intracellular death domain of TNFR1 and acts as a central platform that couples TNF receptor engagement to distinct programs of NF‑κB activation, apoptosis, and necrotic cell death. The C‑terminal death domain of TRADD is sufficient for interaction with the TNFR1 death domain and for initiating both NF‑κB activation and programmed cell death, while the N‑terminal region provides binding interfaces for TRAF2 and other signaling components, allowing TRADD to assemble receptor-proximal complexes with defined composition and output. Upon trimeric TNFα binding to TNFR1, conformational change in the receptor permits recruitment of TRADD, which then nucleates formation of a membrane-associated “complex I” by binding TRAF2, cIAPs and RIP1; in this configuration, K63-linked ubiquitination of RIP1 and scaffold activity of TRAF2 support activation of the IKK complex and MAP kinases, leading to NF‑κB–dependent transcription of genes that promote inflammation, survival and, in many contexts, suppression of apoptotic signaling. TRADD simultaneously provides a bifurcation point for death signaling: its direct interaction with TRAF2 preferentially drives NF‑κB activation, whereas its direct interaction with FADD/MORT1 via homotypic death domain contacts seeds formation of a secondary cytosolic “complex II” containing FADD and caspase‑8 that can execute apoptosis when survival signals are compromised. Dominant-negative TRAF2 mutants that lack the N‑terminal RING finger inhibit TNF‑mediated NF‑κB activation without affecting apoptosis, while dominant-negative FADD mutants lacking the N‑terminal portion block TNF‑induced apoptosis but leave NF‑κB activation intact, demonstrating that the two TNFR1–TRADD signaling cascades diverge at TRADD into TRAF2‑dependent survival/inflammatory signaling and FADD‑dependent apoptotic signaling. TRADD also participates in TRIF-dependent Toll-like receptor pathways: TRADD-deficient mice show abrogated TNF-induced apoptosis, impaired recruitment of TRAF2 and RIP1 ubiquitination at TNFR1, markedly reduced but not fully abolished NF‑κB and MAPK activation downstream of TNFR1, and reduced TRIF-dependent cytokine production and NF‑κB/MAPK activation in fibroblasts in response to TLR3 and TLR4 agonists, indicating that TRADD is essential for TNFR1 signaling and exerts cell type–specific control in TLR-mediated inflammatory responses. Structural analysis of the TRADD death domain reveals a novel fold within the death-domain superfamily comprising an all‑helix Greek key motif plus a β‑hairpin flanked by helices that creates a highly charged surface conducive to electrostatic interactions with other death-domain proteins, providing a structural basis for homotypic DD pairing with TNFR1, FADD, RIP1 and p75 neurotrophin receptor and explaining how TRADD can mediate both receptor binding and assembly of multiple distinct signaling complexes. Functional dissection further shows that TRADD and RIP1 compete for recruitment to TNFR1; TRADD is required for TNFR1-induced NF‑κB activation and caspase‑8–dependent apoptosis but dispensable for TNFR1-initiated, RIP1-dependent necrosis, so the balance between TRADD and RIP1 association at the receptor determines whether TNF signaling favors survival/inflammation, apoptotic death or necrotic death programs. These mechanistic insights define TRADD as a structurally unique death-domain adaptor whose N‑ and C‑terminal regions orchestrate assembly of TRAF2-, RIP1- and FADD-containing complexes downstream of TNFR1 and TRIF, and whose recruitment and competition with RIP1 at the receptor-proximal level set the trajectory of TNF/TLR signaling toward NF‑κB activation, caspase‑8–mediated apoptosis or necrosis, making TRADD an informative target for probing and modulating death receptor and innate immune pathways in cancer, autoimmunity and inflammatory disease.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください